Melperone Abz (Melperone Hydrochloride)

Melperone, a butyrophenone antipsychotic, is employed in the treatment of psychotic disorders.

• Schizophrenia: helps reduce hallucinations, delusions and thought disorder.
• Acute psychosis: alleviates severe agitation and psychotic symptoms.
• Maintenance therapy: supports long‑term control of psychotic relapse.

• Melperone acts primarily as an antagonist at dopamine D2 receptors and serotonin 5‑HT2 receptors. By blocking D2 receptors, it reduces dopaminergic neurotransmission implicated in psychotic symptoms, while 5‑HT2 antagonism contributes to mood stabilization and mitigates extrapyramidal side effects. The combined receptor profile underlies its antipsychotic efficacy.

Melperone may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects

• Sedation: feeling unusually drowsy or sleepy.
• Orthostatic hypotension: dizziness upon standing.
• Dry mouth: reduced salivation.
• Constipation: slowed gastrointestinal motility.
• Weight gain: increase in body weight.
• Extrapyramidal symptoms: mild tremor or rigidity.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening fever and muscle rigidity.
• Tardive dyskinesia: persistent involuntary movements.
• Agranulocytosis: severe reduction in white blood cells.
• Seizures: increased risk of convulsive episodes.
• Cardiac arrhythmia: abnormal heart rhythm, especially QT prolongation.
• Severe hypotension: marked drop in blood pressure leading to fainting.

When prescribing Melperone, clinicians should consider several safety measures.

• Monitor extrapyramidal symptoms: assess for tremor, rigidity or dyskinesia regularly.
• Cardiovascular assessment: check blood pressure and ECG for QT interval changes.
• Metabolic monitoring: observe weight, glucose and lipid levels during long‑term therapy.
• Avoid in known hypersensitivity: discontinue if allergic reactions occur.
• Use caution in elderly with dementia: increased risk of cerebrovascular events.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Store below 25°C: keep in the original pack, protect from moisture.

Melperone can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise melperone plasma levels.
• QT‑prolonging agents (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmia.
• Other antipsychotics: additive central nervous system depression.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, alcohol): enhance sedation.
• Antihypertensives: may potentiate orthostatic hypotension.
• Anticholinergic drugs: could worsen dry mouth and constipation.
• Lithium: monitor for neurotoxicity.
• Carbamazepine: may reduce melperone effectiveness.